Workup to Rule Out Cushing Syndrome

Initial Evaluation

• Obtain a comprehensive medication history to exclude iatrogenic glucocorticoid exposure before any biochemical testing. This mandatory first step prevents false‑positive screening results. [1][2]3

First‑Line Screening Tests

24‑Hour Urinary Free Cortisol (UFC)

• Collect at least two separate 24‑hour urine samples; UFC reflects integrated cortisol production and is independent of changes in corticosteroid‑binding globulin. 4
• Avoid UFC in patients with renal impairment (creatinine clearance < 60 mL/min) or marked polyuria (>5 L/24 h) because urine collection may be inaccurate. 4
• In severe renal failure, use the overnight dexamethasone suppression test (DST) instead. [3][5]
• UFC values > 3‑fold the upper limit of normal strongly suggest true Cushing syndrome rather than pseudo‑Cushing. 4

Late‑Night Salivary Cortisol (LNSC)

• Collect at least two salivary samples between 11 pm and midnight; loss of the normal circadian rhythm in Cushing syndrome makes this test sensitive. 4
• LNSC is preferred for shift‑workers, suspected cyclic Cushing syndrome, and for outpatient convenience. [4][5]3
• When an adrenal tumor is suspected, measure both cortisol and cortisone to avoid false‑positive results due to 11β‑HSD2 deficiency. 4

1‑mg Overnight Dexamethasone Suppression Test (DST)

• Administer 1 mg dexamethasone at 11 pm and measure serum cortisol at 8 am; a cortisol > 1.8 µg/dL (50 nmol/L) indicates Cushing syndrome. [2][6]
• DST is preferred for evaluating adrenal incidentalomas and for patients with renal failure. [4][5]3
• Interpret with caution or avoid DST in:
  
  • Women taking oral estrogen (increases CBG → false‑positive).
  • Patients on CYP3A4 inducers (phenobarbital, carbamazepine, St John’s wort) → false‑negative.
  • Patients on antiepileptic drugs (use UFC or LNSC instead).
  • Pregnancy (use UFC only).
  • (All above situations supported by guideline evidence). [4][2][5][3]
• Measuring serum dexamethasone levels concurrently can reduce false‑positive results caused by non‑compliance or altered metabolism. 4

Alternative Low‑Dose DST

• A 2‑mg, 48‑hour low‑dose DST is more cumbersome but may provide higher specificity for Cushing syndrome. 2

Interpretation Algorithm

• Concordant positive screening tests (≥ 2 abnormal results) → refer immediately to endocrinology for confirmatory testing and proceed with ACTH measurement to determine etiology. [1][2]7
• Concordant negative screening tests → Cushing syndrome is unlikely; no further work‑up needed. Exception: high clinical suspicion for cyclic Cushing or an adrenal incidentaloma warrants endocrinology referral. Re‑evaluate in 6 months if symptoms evolve. [1][6][5][3]
• Discordant results (one positive, one negative) → obtain a third screening test or specialized tests (e.g., midnight serum cortisol, dexamethasone‑CRH test) and refer to endocrinology for expert interpretation. [1][3][4][1]

Special Populations

• Pregnancy: Use only UFC; DST is contraindicated. [2][5]3
• Cyclic Cushing syndrome: Prefer UFC or LNSC over DST; multiple collections over weeks‑months may be required to capture hypercortisolemic phases. [5][3]4
• Adrenal incidentaloma: For mild autonomous cortisol secretion, use 1‑mg DST or LNSC rather than UFC. [5][3]
• Epilepsy or patients on CYP3A4 inducers: Avoid DST; UFC or LNSC are recommended. [2][5]

Common Pitfalls

• Pseudo‑Cushing states (obesity, depression, alcohol use disorder, PCOS) can cause false‑positive UFC, usually < 3‑fold elevation. 4
• Incomplete 24‑hour urine collections invalidate UFC results; verify adequate volume and creatinine excretion. 4
• Oral estrogen use raises CBG and can falsely elevate cortisol in DST; consider stopping estrogen or switching to UFC/LNSC. 4
• A single abnormal screening test is insufficient; confirm with at least one additional test before invasive work‑up. [4][7]
• Do not use random serum cortisol, plasma ACTH, or urinary 17‑ketosteroids for initial screening of Cushing syndrome. 6

Initial Work‑Up and Screening Strategy for Suspected Cushing’s Disease

Pre‑test Evaluation

• Obtain a comprehensive medication history to rule out exogenous glucocorticoid exposure (oral, inhaled, topical, or injectable) before ordering any biochemical tests. 8

Screening Test Recommendations

Requirement for Multiple Tests

• Perform at least two different biochemical screening tests to confirm hypercortisolism before proceeding to imaging or localization studies. [9][10]

24‑Hour Urinary Free Cortisol (UFC)

• Collect a minimum of two to three separate 24‑hour urine specimens on different days to accommodate day‑to‑day variability. 8

Late‑Night Salivary Cortisol (LNSC)

• Obtain at least two salivary samples between 11 PM and midnight on separate evenings. 8
• Use LNSC preferentially when UFC collection is impractical or unreliable (e.g., shift workers, suspected cyclic Cushing’s). 8

1‑mg Overnight Dexamethasone Suppression Test (DST)

• Administer 1 mg dexamethasone at 11 PM and measure serum cortisol at 8 AM the following morning. 8
• Concurrently measure serum dexamethasone levels to detect non‑compliance or altered metabolism and reduce false‑positive results. 8

Interpretation of Screening Results

Concordant Positive Results (≥ 2 abnormal tests)

• Refer the patient promptly to endocrinology and obtain a plasma ACTH measurement to differentiate ACTH‑dependent (pituitary or ectopic) from ACTH‑independent (adrenal) disease. 8

Concordant Negative Results (≥ 2 normal tests)

• Consider Cushing’s syndrome unlikely; no further diagnostic work‑up is required. [9][10]
• Exception: if clinical suspicion remains high (e.g., progressive signs or adrenal incidentaloma), refer to endocrinology and plan re‑evaluation in approximately six months.

Discordant Results (one positive, one negative)

• Perform a third screening test or specialized assessments (e.g., midnight serum cortisol, dexamethasone‑CRH test). [9][10]
• Refer to endocrinology for expert interpretation, especially when pre‑test probability is high. [9][10]

Post‑Biochemical Confirmation Imaging Pathway

ACTH Assessment

• After two concordant positive screening tests, measure plasma ACTH to guide further imaging. 8

Pituitary Evaluation (ACTH‑dependent)

• Obtain pituitary MRI when ACTH is normal or elevated. 8
  
  • Pituitary lesions ≥ 10 mm are considered definitive for Cushing’s disease; inferior petrosal sinus sampling (IPSS) is not required. 8
  • Lesions < 6 mm mandate IPSS for confirmation. 8
  • Lesions 6–9 mm fall into a gray zone; consider CRH or DDAVP testing or IPSS based on expert opinion. 8

Adrenal Evaluation (ACTH‑independent)

• If ACTH is suppressed, obtain adrenal CT or MRI to identify an adrenal source of excess cortisol. 8